Harika Guduru
Internal Medicine · Aldie, VANPI 1972066769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,100 of the $42,234 with a category attached, or 92.6%. Incyte Corporation accounts for 92.6% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $40,262, more than ten times the $107 reported in 2022. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $322.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$39K
- Novo Nordisk$1K
- Amgen$498
- Lilly USA, LLC$360
- Pfizer$288
- Bayer$230
- plus $726 from 17 others
What the payments were for
- Consulting fees$39,10093%
- Food & beverage$3,1347%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $39,100 |
| Novo Nordisk | 33 | $1,032 |
| Amgen | 23 | $498 |
| Lilly USA, LLC | 21 | $360 |
| Pfizer | 14 | $288 |
| Bayer | 8 | $230 |
| AstraZeneca | 7 | $191 |
| Medtronic | 1 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Novartis | 3 | $60 |
| Optinose US, Inc. | 2 | $50 |
| Exact Sciences | 2 | $37 |
| GSK | 2 | $35 |
| Acella Pharmaceuticals, LLC | 2 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| AbbVie | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Coala Life Inc | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$117
How this compares
$42,234 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $27,044 |
| JardianceEmpagliflozin | 12 | $17,902 |
| TrulicityDulaglutide | 13 | $12,370 |
| Rosuvastatin Calcium | 48 | $680 |
| Valsartan | 12 | $445 |
| Losartan Potassium | 42 | $234 |
| Amlodipine Besylate | 25 | $213 |
| Olmesartan Medoxomil | 15 | $182 |
| Metformin Hcl ErMetformin Hcl | 21 | $179 |
| Levothyroxine Sodium | 39 | $165 |
| Pravastatin Sodium | 12 | $163 |
| Atorvastatin Calcium | 24 | $151 |
| Omeprazole | 11 | $148 |
| Metoprolol Succinate | 12 | $115 |
| Lisinopril | 26 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,032 | $27,04415 claims |
| Boehringer IngelheimJardiance | $20 | $17,90212 claims |
| Lilly USA, LLCTrulicity | $360 | $12,37013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Aldie
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.